Dan Angelov

@dr-chromatin.bsky.social

Physician-Scientist. Haematologist - Lymphoma. Functional Genomics in Blood Cancers. Chromatin Biology.

Absolutely delighted to share our preprint, using functional genomics to uncover a novel dependency in lymphoma that can overcome resistance to targeted therapy. Grateful to co-first author @jamesnolan.bsky.social and co-senior authors @conwayer1.bsky.social and @adrianbracken.bsky.social see👇

James Nolan@jamesnolan.bsky.social · 10mo ago

🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇 #CancerResearch #Epigenetics #Chromatin #Lymphoma

Please see 🧵by @evhealy.bsky.social about our new paper exploring the role of PRC1 and PRC2 in non-dividing cells 👇

Evan Healy@evhealy.bsky.social · 2y ago

🧵 1/ We’re excited to share that our new paper with @adrianbracken.bsky.social lab is out 🎉 In this study (which began over 10 years ago!), we explore the biology of PRC2 and PRC1 in non-dividing cells. We also explore the effects of PRC2 inhibitor drugs on these cells. Here’s what we found👇

The Groth lab @grothlab.bsky.social has also made the jump from X to Bluesky🤩! Please follow us for all things related to chromatin replication, epigenetic memory and (epi)genome stability in the context of mitotic cell division! We'll start on joining some relevant starter packs!

This is amazing. Menin inhibitors FDA approved! Such a quick turnaround from drug discovery, to molecular mechanisms and on to clinical trials showing efficacy and favourable safety profile. A huge win for the field of epigenetic targeted drugs! Kudos to all involved. www.fda.gov/drugs/resour...

FDA approves revumenib for relapsed or refractory acute leukemia

On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.

fda.gov